Investor Relations

WILMINGTON, Mass.--(BUSINESS WIRE)--Apr. 3, 2017-- Charles River Laboratories International, Inc. (NYSE: CRL), a leading early-stage contract research organization (CRO), announced the North American launch of its triple-immunodeficient mouse model, known as the NCG model. The NCG model is the first CRISPR-generated immunodeficient model offered by Charles River, and was developed by altering the Prkdc and Il2rg genes.

“The launch of Charles River’s NCG model provides a significant opportunity to assist our clients in the development of life-saving, translational therapies,” said Dr. Iva Morse, Corporate Vice President, Chief Scientific Officer, Global Research Models and Services. “The availability of this model, combined with our scientific expertise, will allow us to work with clients to advance the application of humanized studies in oncology, among other therapeutic areas.”

The NCG model was co-developed by the Nanjing Biomedical Research Institute of Nanjing University and Nanjing Galaxy Biopharma, and transferred to Charles River in 2016. The NCG model is similar to other triple-immunodeficient models in that it is capable of hosting xenograft cells, tissue, and human immune system components, enabling researchers to further study tumor biology and immuno-oncology.

This model complements Charles River’s extensive portfolio of oncology products and services, including studies in human xenograft, syngeneic, and humanized immunotherapy research models, flow cytometry, and IVIS^® imaging services. In November 2015, the Company acquired Oncotest GmbH, a Freiburg, Germany-based organization with a specialization in patient-derived xenograft (PDX) models, and in November 2016, partnered with OcellO to provide translational in vitro PDX and in vivo PDX oncology drug discovery services.

Charles River is introducing the NCG model to its North American customer base at the 2017 AACR Annual Meeting, which highlights the best cancer science and medicine from institutions all over the world. A full schedule of Charles River’s activities during the 2017 AACR Annual Meeting is available on their website, and reprints of each poster are available in Charles River’s booth (#1421) during the conference. Additionally, experts are available to discuss the NCG model, as well as their capabilities and expertise in oncology research. Throughout the conference, Charles River will be providing live updates on the Eureka Blog, including reviews of scientific sessions and input on the research being presented.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170403005053/en/

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
amy.cianciaruso@crl.com
or
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com